News & Updates
Filter by Specialty:
![MET amplification a predictor of response to crizotinib](https://sitmspst.blob.core.windows.net/images/articles/fish-73a7e52b-da4e-422d-8583-5d6854728b77-square.jpg)
MET amplification a predictor of response to crizotinib
A subanalysis of the ongoing phase II PROFILE 1001 study suggests that MET amplification may serve as one of the predictive biomarkers for response to crizotinib among patients with non-small-cell lung cancer (NSCLC).
MET amplification a predictor of response to crizotinib
12 Oct 2021![Recovered mothers transfer SARS-CoV-2 antibodies to newborns](https://sitmspst.blob.core.windows.net/images/articles/maternal-abs-3b4dade2-dd27-45b8-a6b5-5b1b1010ef87-square.jpg)
Recovered mothers transfer SARS-CoV-2 antibodies to newborns
A Hong Kong study demonstrates vertical transfer of antibodies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to babies whose mothers have recovered from coronavirus disease 2019 (COVID-19).
Recovered mothers transfer SARS-CoV-2 antibodies to newborns
12 Oct 2021![Tamibaroterone inhalable dry powder shows broad-spectrum activity against SARS-CoV-2, MERS and H1N1](https://sitmspst.blob.core.windows.net/images/articles/dry-powder-31da2f8c-eefa-48ad-a3a7-5b7c06e0d76b-square.jpg)
Tamibaroterone inhalable dry powder shows broad-spectrum activity against SARS-CoV-2, MERS and H1N1
Researchers from the University of Hong Kong (HKU) have developed a dry powder formulation of tamibaroterone, which displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic 2009 influenza A virus (H1N1), when delivered intranasally or through inhalation in mouse and hamster models.
Tamibaroterone inhalable dry powder shows broad-spectrum activity against SARS-CoV-2, MERS and H1N1
12 Oct 2021![Early convalescent plasma infusion does not prevent COVID-19 progression](https://sitmspst.blob.core.windows.net/images/articles/early-convalescent-plasma-infusion-does-not-prevent-covid-19-progression-57fb3e2b-cee6-4d48-8dfb-77a67fde02d2-square.jpg)
Early convalescent plasma infusion does not prevent COVID-19 progression
An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.
Early convalescent plasma infusion does not prevent COVID-19 progression
11 Oct 2021![Diet plus exercise keeps BP in check for patients with resistant hypertension](https://sitmspst.blob.core.windows.net/images/articles/exercise-and-diet-583b086d-cc11-43b6-9150-355bba93670a-square.jpg)
Diet plus exercise keeps BP in check for patients with resistant hypertension
A structured lifestyle modification programme that combines a healthy eating plan and regular aerobic exercise promotes blood pressure (BP) control and improves cardiovascular disease biomarkers in patients with resistant hypertension, as shown in the TRIUMPH study.